Llwytho...
In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
BACKGROUND: Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1–infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical reports of dolutegravir for HIV-2 are limited. To evaluate the potential role o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Retrovirology |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
BioMed Central
2015
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4328052/ https://ncbi.nlm.nih.gov/pubmed/25808007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12977-015-0146-8 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|